Humacyte Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

HumacyteDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -4.4% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 55.7% pro Jahr.

Wichtige Informationen

-4.4%

Wachstumsrate der Gewinne

79.0%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-55.7%
Eigenkapitalrendite	-404.2%
Netto-Marge	n/a
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Jun 05

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

May 14

Aufschlüsselung der Einnahmen und Ausgaben

Wie Humacyte Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:HUMA Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten
31 Mar 24	0	-106	20
31 Dec 23	0	-111	20
30 Sep 23	0	-89	20
30 Jun 23	0	-89	20
31 Mar 23	1	-29	22
31 Dec 22	2	-12	23
30 Sep 22	2	34	23
30 Jun 22	2	28	22
31 Mar 22	1	-26	22
31 Dec 21	1	-26	21
30 Sep 21	1	-85	18
30 Jun 21	2	-71	16
31 Mar 21	1	-69	14
31 Dec 20	1	-67	12
31 Dec 19	6	-85	16

Qualität der Erträge: HUMA ist derzeit unrentabel.

Wachsende Gewinnspanne: HUMA ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: HUMA ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 4.4% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von HUMA verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: HUMA ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: HUMA hat eine negative Eigenkapitalrendite (-404.19%), da es derzeit unrentabel ist.

Humacyte Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Recent updates

Independent Chairman of the Board exercised options to buy US$234k worth of stock.

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Chief Operating Officer recently sold US$502k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director recently bought US$668k worth of stock

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Humacyte, Inc. to Report Q1, 2024 Results on May 10, 2024

Humacyte, Inc., Annual General Meeting, Jun 11, 2024

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target increased by 7.1% to US$7.50

New major risk - Revenue and earnings growth

Humacyte, Inc. to Report Q4, 2023 Results on Mar 22, 2024

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

New minor risk - Shareholder dilution

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $40.2 million.

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

Humacyte, Inc. Announces U.S. Food and Drug Administration Accepts and Grants Priority Review to Humacyte's Biologics License Application

New minor risk - Share price stability

Consensus revenue estimates decrease by 12%

Humacyte, Inc. Submits Biologics License Application to U.S. Food and Drug Administration Seeking Approval of Human Acellular Vessel (Hav) for the Treatment of Vascular Trauma

Humacyte, Inc. Announces Presentations of Positive Clinical Results of the Human Acellular Vessel™? (HAV™?) in the Treatment of Vascular Trauma

Humacyte, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Humacyte, Inc. Publishes Preclinical Results Showing Human Acellular Vessel™? Patency as Modified Blalock-Taussig-Thomas Shunt in Juvenile Primate Model

Founder exercised options to buy US$280k worth of stock.

Humacyte, Inc. Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™? (HAV™?) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. Announces the Presentation of Results from FDA Regulated, Investigator-Sponsored Clinical Study Conducted At the Mayo Clinic

Consensus revenue estimates fall by 33%

Humacyte, Inc. Presents Clinical Performance of Human Acellular Vessel (HAV) from Ukrainian Humanitarian Program

New major risk - Revenue size

First half 2023 earnings released: US$0.58 loss per share (vs US$0.17 profit in 1H 2022)

Humacyte, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel

Humacyte, Inc. Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel(Tm) (Hav(Tm)) for Vascular Trauma Repair

Chief Operating Officer exercised options to buy US$240k worth of stock.

First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.19 loss in 1Q 2022)

Humacyte, Inc. to Report Q1, 2023 Results on May 12, 2023

Price target decreased by 24% to US$7.35

Consensus revenue estimates decrease by 45%, EPS upgraded

Price target decreased by 15% to US$9.46

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 16%

Founder exercised options to buy US$321k worth of stock.

Investor sentiment improves as stock rises 15%

Humacyte, Inc. Announces Publication of 6-Year Outcomes of Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, in Journal of Vascular Surgery – Vascular Science

Key Executive recently bought US$52k worth of stock

Investor sentiment deteriorated over the past week

Consensus EPS estimates fall by 13%

High number of new directors

Price target decreased to US$10.13

Consensus EPS estimates fall by 12%

Humacyte, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Humacyte: Intriguing Potential

Humacyte, Inc. Announces New Board Appointments

Investor sentiment improved over the past week

Independent Director recently bought US$193k worth of stock

Investor sentiment deteriorated over the past week

Consensus revenue estimates increase by 126%

Price target decreased to US$11.25

Second quarter 2022 earnings released: EPS: US$0.36 (vs US$0.76 loss in 2Q 2021)

Humacyte GAAP EPS of $0.35, revenue of $1.3M

Humacyte, Inc. to Report Q2, 2022 Results on Aug 12, 2022

High number of new directors

Humacyte, Inc. Announces Results Evaluating the Use of the Small-Diameter (3.5mm) Human Acellular Vessel for Coronary Artery Bypass Grafting in a Non-Human Primate Model

High number of new directors

Humacyte, Inc. Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel(TM) (HAV(TM)) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options

Humacyte, Inc. Appoints Diane Seimetz to its Board of Directors

Humacyte, Inc. Presents New Immunogenicity Data on Human Acellular Vessels(Tm) (Havs(Tm))

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Humacyte, Inc. to Report Q1, 2022 Results on May 13, 2022